Literature DB >> 33706638

The role of discoidin domain receptor 2 in the renal dysfunction of alport syndrome mouse model.

Yuya Sannomiya1, Shota Kaseda1,2, Misato Kamura1,2, Hiroshi Yamamoto3, Hiroyuki Yamada3, Masataka Inamoto3, Jun Kuwazuru1, Saki Niino1, Tsuyoshi Shuto1,4, Mary Ann Suico1,4, Hirofumi Kai1,2,4.   

Abstract

Alport syndrome (AS) is a hereditary glomerular nephritis caused by mutation in one of the type IV collagen genes α3/α4/α5 that encode the heterotrimer COL4A3/4/5. Failure to form a heterotrimer due to mutation leads to the dysfunction of the glomerular basement membrane, and end-stage renal disease. Previous reports have suggested the involvement of the receptor tyrosine kinase discoidin domain receptor (DDR) 1 in the progression of AS pathology. However, due to the similarity between DDR1 and DDR2, the role of DDR2 in AS pathology is unclear. Here, we investigated the involvement of DDR2 in AS using the X-linked AS mouse model. Mice were treated subcutaneously with saline or antisense oligonucleotide (ASO; 5 mg/kg or 15 mg/kg per week) for 8 weeks. Renal function parameters and renal histology were analyzed, and the gene expressions of inflammatory cytokines were determined in renal tissues. The expression level of DDR2 was highly elevated in kidney tissues of AS mice. Knockdown of Ddr2 using Ddr2-specific ASO decreased the Ddr2 expression. However, the DDR2 ASO treatment did not improve the proteinuria or decrease the BUN level. DDR2 ASO also did not significantly ameliorate the renal injury, inflammation and fibrosis in AS mice. These results showed that Ddr2 knockdown by ASO had no notable effect on the progression of AS indicating that DDR2 may not be critically involved in AS pathology. This finding may provide useful information and further understanding of the role of DDRs in AS.

Entities:  

Keywords:  Alport syndrome; Type IV collagen; discoidin domain receptor 2 (DDR2); fibrosis; inflammatory cytokines; proteinuria

Year:  2021        PMID: 33706638      PMCID: PMC7971217          DOI: 10.1080/0886022X.2021.1896548

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  32 in total

Review 1.  Sensing extracellular matrix: an update on discoidin domain receptor function.

Authors:  Wolfgang F Vogel; Rahim Abdulhussein; Caroline E Ford
Journal:  Cell Signal       Date:  2006-02-28       Impact factor: 4.315

2.  PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression.

Authors:  Hyeyoung Nam; Anirban Kundu; Garrett J Brinkley; Darshan S Chandrashekar; Richard L Kirkman; Balabhadrapatruni V S K Chakravarthi; Rachael M Orlandella; Lyse A Norian; Guru Sonpavde; Pooja Ghatalia; Fei Fei; Shi Wei; Sooryanarayana Varambally; Sunil Sudarshan
Journal:  Matrix Biol       Date:  2020-01-23       Impact factor: 11.583

3.  The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling.

Authors:  Petros Andrikopoulos; Julius Kieswich; Sabrina Pacheco; Luxme Nadarajah; Steven Michael Harwood; Caroline E O'Riordan; Christoph Thiemermann; Muhammad M Yaqoob
Journal:  J Am Soc Nephrol       Date:  2018-12-10       Impact factor: 10.121

4.  The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism.

Authors:  J P Labrador; V Azcoitia; J Tuckermann; C Lin; E Olaso; S Mañes; K Brückner; J L Goergen; G Lemke; G Yancopoulos; P Angel; C Martínez; R Klein
Journal:  EMBO Rep       Date:  2001-05       Impact factor: 8.807

5.  Podocyte p53 Limits the Severity of Experimental Alport Syndrome.

Authors:  Ryosuke Fukuda; Mary Ann Suico; Yukari Kai; Kohei Omachi; Keishi Motomura; Tomoaki Koga; Yoshihiro Komohara; Kosuke Koyama; Tsubasa Yokota; Manabu Taura; Tsuyoshi Shuto; Hirofumi Kai
Journal:  J Am Soc Nephrol       Date:  2015-05-12       Impact factor: 10.121

6.  Transcriptional upregulation of DDR2 by ATF4 facilitates osteoblastic differentiation through p38 MAPK-mediated Runx2 activation.

Authors:  Kuan-Liang Lin; Ching-Heng Chou; Shu-Chen Hsieh; Su-Yang Hwa; Ming-Ta Lee; Fung-Fang Wang
Journal:  J Bone Miner Res       Date:  2010-11       Impact factor: 6.741

7.  Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse model.

Authors:  Kohei Omachi; Rui Miyakita; Ryosuke Fukuda; Yukari Kai; Mary Ann Suico; Tsubasa Yokota; Misato Kamura; Tsuyoshi Shuto; Hirofumi Kai
Journal:  Clin Exp Nephrol       Date:  2017-02-08       Impact factor: 2.801

8.  STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model.

Authors:  Tsubasa Yokota; Kohei Omachi; Mary Ann Suico; Misato Kamura; Haruka Kojima; Ryosuke Fukuda; Keishi Motomura; Keisuke Teramoto; Shota Kaseda; Jun Kuwazuru; Toru Takeo; Naomi Nakagata; Tsuyoshi Shuto; Hirofumi Kai
Journal:  Nephrol Dial Transplant       Date:  2018-02-01       Impact factor: 5.992

9.  Discoidin domain receptor 1 promotes Th17 cell migration by activating the RhoA/ROCK/MAPK/ERK signaling pathway.

Authors:  Mohammed-Amine El Azreq; Maleck Kadiri; Marc Boisvert; Nathalie Pagé; Philippe A Tessier; Fawzi Aoudjit
Journal:  Oncotarget       Date:  2016-07-19

10.  DNA-Encoded Library-Derived DDR1 Inhibitor Prevents Fibrosis and Renal Function Loss in a Genetic Mouse Model of Alport Syndrome.

Authors:  Hans Richter; Alexander L Satz; Marc Bedoucha; Bernd Buettelmann; Ann C Petersen; Anja Harmeier; Ricardo Hermosilla; Remo Hochstrasser; Dominique Burger; Bernard Gsell; Rodolfo Gasser; Sylwia Huber; Melanie N Hug; Buelent Kocer; Bernd Kuhn; Martin Ritter; Markus G Rudolph; Franziska Weibel; Judith Molina-David; Jin-Ju Kim; Javier Varona Santos; Martine Stihle; Guy J Georges; R Daniel Bonfil; Rafael Fridman; Sabine Uhles; Solange Moll; Christian Faul; Alessia Fornoni; Marco Prunotto
Journal:  ACS Chem Biol       Date:  2018-12-16       Impact factor: 5.100

View more
  3 in total

1.  Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates Progressive Phenotype in Alport Syndrome Mouse Model.

Authors:  Shota Kaseda; Yuya Sannomiya; Jun Horizono; Jun Kuwazuru; Mary Ann Suico; Sayaka Ogi; Ryoko Sasaki; Hidetoshi Sunamoto; Hirohiko Fukiya; Hayato Nishiyama; Misato Kamura; Saki Niinou; Yuimi Koyama; Futoshi Nara; Tsuyoshi Shuto; Kazuhiro Onuma; Hirofumi Kai
Journal:  Kidney360       Date:  2021-12-01

Review 2.  Molecular Basis, Diagnostic Challenges and Therapeutic Approaches of Alport Syndrome: A Primer for Clinicians.

Authors:  Raquel Martínez-Pulleiro; María García-Murias; Manuel Fidalgo-Díaz; Miguel Ángel García-González
Journal:  Int J Mol Sci       Date:  2021-10-14       Impact factor: 5.923

Review 3.  Genetic and pharmacological tools to study the role of discoidin domain receptors in kidney disease.

Authors:  Corina M Borza; Gema Bolas; Ambra Pozzi
Journal:  Front Pharmacol       Date:  2022-09-28       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.